Core Viewpoint - Medline Inc. has successfully completed its upsized initial public offering (IPO) of 248,439,654 shares of Class A common stock at a price of $29.00 per share, including the underwriters' option to purchase an additional 32,405,172 shares [1] Group 1: IPO Details - The proceeds from the issuance of 179,000,000 shares will be used to repay outstanding indebtedness under senior secured term loan facilities, with the remainder allocated for general corporate purposes and offering expenses [2] - Medline plans to use proceeds from the issuance of 37,034,482 shares and the additional shares purchased by underwriters to buy or redeem an equivalent number of outstanding equity interests from certain pre-IPO owners [2] - The Class A common stock of Medline is listed on the Nasdaq Global Select Market under the symbol "MDLN" [2] Group 2: Underwriters and Managers - Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan acted as global coordinators and lead bookrunning managers for the offering [2] - A wide range of firms, including Barclays, Citigroup, and Deutsche Bank Securities, served as bookrunning managers, while numerous others acted as co-managers for the offering [2] Group 3: Company Overview - Medline is the largest provider of medical-surgical products and supply chain solutions, serving all points of care [5] - The company has a broad product portfolio, resilient supply chain, and leading clinical solutions aimed at improving clinical, financial, and operational outcomes for healthcare providers [5] - Headquartered in Northfield, Illinois, Medline employs over 43,000 people globally and operates in more than 100 countries [5]
Medline Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares